ICYMI, here's yesterday's piece for Scrip, Citeline Commercial on the companies aiming to follow $BMY in schizophrenia: scrip.citeline.com/articles/2024/…

ICYMI yesterday, I had a look at the Q4 obesity readouts coming for $NVO's cagrisema and $AMGN's MariTide. This is a paywall-free read, but arguably not a comfortable one. insights.citeline.com//scrip/r-and-d…

Drug development is tricky, it turns out. Following AbbVie's blow-up in schizophrenia, my Scrip, Citeline Commercial piece from September shows the projects that are still in the running: insights.citeline.com/SC150953/Follo…

$AMGN's MariTide data are finally out. Here's my preview of the readout from last month, which also looks at the terrifyingly high expectations for $NVO's cagrisema.

We've noticed a huge number of people in the science and medical community joining bluesky . Endpoints and many of our journalists are already there (we're still on here and LinkedIn). You can find us through our starter pack, come say hi! go.bsky.app/NzDRUhL

Now updated and with new version of the chart! $NVO $LLY $VKTX $RHHBY

Happy new year! My first Endpoints News article of 2025 looks at how obesity pills - potentially the next big market - stack up: endpts.com/after-cagrisem…

$ZEAL finally got its petre partner - and it's *drumroll* $RHHBY! $1.4B upfront, $5.3 in biobucks. Not bad. endpts.com/zealand-partne…

Join me Wednesday, March 26 for Endpoints News inaugural science-focused event, Endpoints Catalysts, where I'll be interviewing leaders in CRISPR gene editing, cell atlases + spatial biology, and regenerative medicine. events.endpts.com/catalysts25

$PFE has dropped its obesity pill danuglipron: endpts.com/in-a-blow-to-i…

$LLY's oral GLP-1 looks good in diabetes, but the real test is the upcoming obesity readout. Nice piece from Max Gelman here: endpts.com/eli-lilly-repo…

🎙️Let's talk "most favored nation"! Today on Post-Hoc Live, I'll be joined by biotech lobbyist Nick Shipley to unpack the last 24 hours of Trump's drug pricing exec order, how it would work (or not), unintended consequences + what happens next. Join us! endpts.com/endpoints-live…

Live today at 3 p.m. ET: Is biotech sentiment really as bad as it seems? Join Endpoints' John Carroll, Drew Armstrong, and Kyle LaHucik for a deep dive into the latest Endpoints 100 survey. endpts.com/endpoints-live…

Summit says PD-1xVEGF bispecific ivonsecimab misses overall survival in closely-watched lung cancer study $SMMT endpts.com/summit-says-bi…

🎙️ Today on Endpoints News Post-Hoc Live, we're talking about Sarepta Therapeutics. I'll be joined at 1:30pm by Jared Whitlock and Lei Lei Wu about the company's showdown with the FDA over its hashtag #duchenne gene therapy + what comes next endpoints.news/endpoints-live…

Eli Lilly’s obesity pill is less effective than Novo Nordisk’s, pivotal data suggest - endpoints.news/eli-lillys-obe…

In light of $LLY's orforglipron disappointment, I had a look at the other pills in development for obesity: endpoints.news/obesity-pill-c…

TODAY at 11:30am ET, Adm. Brett Giroir joins Post-Hoc Live to talk to Drew Armstrong and I about the US' exiling of mRNA research. Giroir was the Assistant Secretary for Health in Trump 1.0, and worked at DARPA earlier in his career. endpoints.news/endpoints-live…